Naloxon Inresa (Naloxone Hydrochloride Dihydrate)

Naloxone binds competitively to μ‑opioid receptors without activating them, displacing opioid molecules that are causing sedation or respiratory depression. This blockade quickly restores normal neuronal activity and breathing.

The appropriate dose of Naloxon Inresa is determined by the prescribing clinician based on the patient’s condition, route of administration, and severity of opioid toxicity. Dosage may vary between intramuscular and intravenous routes.

Safety data for naloxone in pregnancy and lactation are limited, and the pregnancy category is unknown. Clinicians should weigh potential benefits against risks and consider alternative treatments when possible.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Naloxon Inresa provides the same rapid opioid‑reversal activity as other naloxone products. Compared with longer‑acting antagonists such as naltrexone, naloxone has a shorter half‑life, making it ideal for acute emergency use where quick onset and short duration are desired.

Naloxon Inresa should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. Do not freeze or shake the vial. If temporary storage at controlled room temperature is unavoidable, limit exposure to less than 30 °C for no more than 24 hours.

Naloxon Inresa is supplied as a sterile injectable solution for intramuscular or intravenous injection. The route and speed of administration are determined by the healthcare professional based on the clinical scenario and patient response.

Serious risks include rapid onset of acute opioid withdrawal, hypertension, cardiac arrhythmias, seizures, and rare anaphylactic reactions. Immediate medical monitoring is essential after administration to manage these potential complications.

Naloxon Inresa should be avoided in individuals with known hypersensitivity to naloxone or any component of the formulation. Caution is advised for patients with severe cardiovascular disease, uncontrolled hypertension, or those receiving mixed agonist‑antagonist opioids.